CollPlant Biotechnologies Ltd(CLGN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 21 at 4:00 PM ET (Korea 10/22 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -9.38 | Insider Own | 14.02% | Shs Outstand | 1.9M | Perf Week | -9.08% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 1.6M | Perf Month | -2.47% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 8.7% | Short Float | 2.59% | Perf Quarter | 20.2% |
| Income | -0.01B | P/S | 22.18 | EPS this Y | - | Inst Trans | 3.52% | Short Ratio | 0.12 | Perf Half Y | -4.28% |
| Sales | 0.00B | P/B | 1.84 | EPS next 5Y | - | ROA | -101.59% | Short Interest | 0.04M | Perf YTD | -73.18% |
| Book/sh | 2.04 | P/C | 2.41 | EPS past 3/5Y | 15.02% -2.35% | ROE | -161.98% | 52W High | -85.56% ($26.00) | Perf Year | -84.16% |
| Cash/sh | 1.56 | P/FCF | - | Sales past 3/5Y | 99.41% -17.32% | ROIC | -265.61% | 52W Low | 42.4% ($2.64) | Perf 3Y | -92.69% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 16.63% | Gross Margin | -587.74% | Volatility(W/M) | 8.18% 10.7% | Perf 5Y | -98.12% |
| Dividend TTM | - | EV/Sales | 21.27 | Sales Y/Y TTM | -86.76% | Oper. Margin | -3900.94% | ATR (14) | 0.43 | Perf 10Y | -97.9% |
| Dividend Ex-Date | - | Quick Ratio | 1.35 | EPS Q/Q | 33.15% | Profit Margin | -3934.91% | RSI (14) | 50.63 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.57 | Sales Q/Q | -39.66% | SMA20 | -0.05% ($3.76) | Beta | 0.62 | Target Price | $120 |
| Payout | - | Debt/Eq | 0.9 | Earnings | 2026/9/30 | SMA50 | 4.63% ($3.59) | Rel Volume | 0.03 | Prev Close | $3.88 |
| Employees | 39 | LT Debt/Eq | 0.6 | EPS/Sales Surpr. | - | SMA200 | -31.78% ($5.51) | Avg Volume(3M) | 0.36M | Price | $3.76 |
| IPO | 2015/5/21 | Option/Short | No/Yes | Trades | 243 | Volume | 9,727 | Change | -3.22% |
🌱 An Israeli biotech company developing regenerative medicine and aesthetic medicine solutions based on recombinant human collagen (rhCollagen) extracted from plants. It holds a diverse product portfolio, including dermal fillers, 3D bioprinted breast implants, medical devices for tendon injuries and chronic wounds, and bioink for bioprinting. The company is headquartered in Rehovot, Israel.
Over the past 1 year, on the lower side
86% below its 1-year high.
Traded less than usual. That is 3% of its average volume.
CLGN has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,218. Peers typically go for $1,173.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -98.1%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 8.7%.
Tap to view numbers
It ranks #524 of 595 in the industry
Based on market cap of $7M.
SKYE#522 Skye Bioscience Inc $7M PER - 
CNSP#523 Cns Pharmaceuticals Inc $7M PER - CLGN#524 CollPlant Biotechnologies Ltd $7M PER - 
APRE#525 Aprea Therapeutics Inc $7M PER - 
AIM#526 AIM ImmunoTech Inc $7M PER - 
FAQ
What kind of company is CLGN?
CLGN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CLGN?
The market cap of CLGN is approximately $7M, ranking 5,524 within its sector.
What is the 52-week high and low for CLGN?
CLGN has recorded a 52-week high of $26.00 and a low of $2.64.
